Clarity Pharmaceuticals Ltd (ASX:CU6)

Australia · Delayed Price · Currency is AUD

2.950

-0.160 (-5.14%)

Apr 28, 2026, 4:10 PM AEST

28.82% (1Y)

Market Cap	1.10B
Revenue (ttm)	10.58M
Net Income (ttm)	-96.35M
Shares Out	372.26M
EPS (ttm)	-0.28
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,996,862
Average Volume	2,671,812
Open	3.100
Previous Close	3.110
Day's Range	2.930 - 3.110
52-Week Range	1.840 - 5.870
Beta	1.31
RSI	44.40
Earnings Date	May 27, 2026

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; an... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 88

Stock Exchange Australian Securities Exchange

Ticker Symbol CU6

Full Company Profile

Financial Performance

In fiscal year 2025, Clarity Pharmaceuticals's revenue was 9.46 million, a decrease of -17.76% compared to the previous year's 11.51 million. Losses were -64.30 million, 51.9% more than in 2024.

Financial Statements

News

Clarity Pharmaceuticals Transcript: AGM 2025

The meeting covered manufacturing expansion, clinical trial progress, and strategic partnerships. Shareholders approved key resolutions, including director re-elections and executive options, while management addressed questions on financials, product strategy, and future M&A opportunities.

5 months ago - Transcripts

Clarity Pharmaceuticals Transcript: AGM 2024

The meeting highlighted strong financial health, major clinical progress in prostate cancer diagnostics and therapy, and a commitment to diversity and governance. Shareholders approved all resolutions, and the company is well positioned for late-phase trials and future growth.

1 year ago - Transcripts